{"ticker": {"uuid": "5acd28d1-e9da-4477-b9cd-96f8a1f7f5f3", "symbol": "IMM", "name": "Immutep Limited", "exchange": "ASX", "country": "AU", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Immutep Shares Rocket Nearly 15% as Immunotherapy Momentum Returns to the ASX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOTmhpZnpnWXRQZWRwbXNHc1JDQV94ZWYwYXhGZ1JfUVN4VDdjMzN0Uk1iaHBjRTgyeUtVd2d3RW1xVGtaY3YzMGp3ODBpcjNZTkQtcW1WbkpQR1FGS196bm1xbS1nb0xpRXZpTlY1NFJiN2dRRlB0MDU4WjVYei1GSjVSRlNEeFk1eDF3UEwwNGtKMmNQcjNzclJCakZLT2ZvenVzMi1Jb1hWV2V5WnR0dzlvTk5NN3Z3?oc=5", "source_name": "Kalkine", "published_at": "2026-07-13T08:19:00+00:00", "published_display": "13 Jul 2026 08:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Immutep (ASX: IMM) Jump 13.73%?", "summary": "", "url": "https://news.google.com/rss/articles/CBMifEFVX3lxTE5XYXlvSlc1MTlaTUt5ZGZuckRQS3RJRzU2Z2Mza3BObkxERjhyN3VFdGFjNDA4V0M2YWhTNzh3d3QtbkdpOXdtdDFtTW5mU0pTZ3J0eWNTVGE5ZDhQQzhtdUY5bUFReUlLZ0ZBU2tJREVuQUx4V01OQ01FM24?oc=5", "source_name": "Kalkine", "published_at": "2026-07-13T06:32:00+00:00", "published_display": "13 Jul 2026 06:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep (ASX:IMM) Shares Surge Nearly 14% as Healthcare Momentum Grabs the ASX Spotlight", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNNmNPd3ZRWmtZRTVBdFNfWWhzVU5pcjdCbkh3U3g2MG5kcnFfNnBiUmtnTWJxbUhWblVHQ1Z1WXdEVlNBQW5ybFduRnpCcElSUVJQbGhCYUxEODMyaDhWRXRSVnNmYy02WkJ5VGVSc2RZNmNTeHIwQmo1RzdiT3BKRkZiX21LY0hoeUt6X2cxTjhQenVKRG5TWTE4bHp1dndtQllxVjlQVXVDSHQ2ZVBUd3dldGR4RU5TWmZxaXlhNVY?oc=5", "source_name": "Kalkine", "published_at": "2026-07-13T04:30:00+00:00", "published_display": "13 Jul 2026 04:30", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep (ASX:IMM) posts 30.9-month survival as TACTI-004 forensics finally get interesting", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxQUFYtZ0FxX2NCaklsY2FSRC1hOFJUSWtaLThGTUphUnRaRUFYQ1JuR0lrTWptWDRia2RmUWhHUkZoQXlwb1F4TURHckY5LWlmQzM2ckNkbHpCQkVIRi02Z3BwU0o0QUtaRkxja3Q0TTMyS0o0N05lN2N0NFdzSllaOGVCZDQ4WVBx?oc=5", "source_name": "Stocks Down Under", "published_at": "2026-07-13T00:41:14+00:00", "published_display": "13 Jul 2026 00:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep (ASX:IMM): Biotech Momentum Returns as This ASX Healthcare Stock Climbs", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxObzk5V3JVM1F3cUNDR3ZwSHpPMDFfQ0lITmlOdkVCUy13cWIzMWhZSUVfTHZfNU9UT2tpV2ZfaXJUNGtsckxWRnVDZWd5eVR0NVBBLV9fb09KY2xWQUcyTzI1SnRrSDBBZC02QlNVdlU4ZXMyamtNSllJNzhoZWVDTXRpUU1hQUlmTkR6cEJuWGFLd0ZLcXVEWkR6MVB3YXl6QVpVTnY1blNYOVBjRmR6RmotZWg?oc=5", "source_name": "Kalkine", "published_at": "2026-07-01T07:37:00+00:00", "published_display": "01 Jul 2026 07:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep (ASX:IMM): Why These ASX Penny Stocks Are Drawing Attention", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNTkRyM1pERUd5VVBnSlgwMGtBcG1iZnUxblVyMEtQZmJydFNjaXFwZVQxdmMtZGk3SFpyZGdKWnlsMEVmS2VTZkFyUVZUczBGMUNsWDJGUTFIVVRaUGtRck5vbkVpTFNoTnE3cEIwajQ2WWRaWmNvSGlCUHRqUi1UTVpFSnJVanlBVmt3VjR1QndfNWpTQ1JZWGtmVmFUTURuMVBIdjBQSmpKWV9hRENiOE15b0I?oc=5", "source_name": "Kalkine Media", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ASX Penny Stocks: Immutep And Two More Companies To Watch", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Watching Immutep's (ASX:IMM) Cash Burn Situation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan Chase Ceases to Be Substantial Holder in Immutep", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOU1FSWUZwYkZkd25wTEJDSlNnejlOb2xMYjBjNnJuUzI4bmUyaERWUjBBeGVobFVaN1k4dEo4OEFKa3FZTWFpZnpFWHNPMXBNZjd4dFJKc0hmZUpEZUg3Rm8tc1ZVM2VUTmRMWGljTGt0bHlJQ1MwU1liU3g2UHZDdzl4R1d4ZHZ1VUtuOE1NaXF1Z0hkb2pyalhra1NEM0FzTGpFY1VXSW9nb09INmc?oc=5", "source_name": "TipRanks", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Immutep (ASX:IMM) In A Good Position To Deliver On Growth Plans?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPdmlqVTd0Qm5NT1gwRXJPUlYtWm9YNmdVaHBGTUJtaExCQ1puSHNWRnFXaVplakxjbTNzZ2tQRWJQa3BHem9GMGlBbjFkNUR5V3ZwOEdxcWE5VU1TLUphN1dwV2kta0pLbzdOdko2QXYyVm1RWmxtcV9kY3RVRDg3UGlOR1M2d0c2U1FZdTRnNG5IRE9ZNEhyTVpB?oc=5", "source_name": "Market source", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ASX Runners of the Week: Bison, Genetic Signatures, Narryer & Immutep", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNSlFJcS1HbWdycUhMaE9ZWFVxcmxlRGN4a2ctRVBYT3RJdFFoejBrZzZNUU51N2d2TmlmcDJUVXFmZTBTQ1lEZEFMR3F0bXlXYmtiRG1HWUtfbi1MMERJLU9zaXF2WFFLSU1RbjAyU0VJcGR0Z0pOQ20yMEdOYWdLZjMta21YaS1RakMtczNGcUJnY1NjSVRkQ1RZMWZPdXdDc1RZTmtNUlU3dzM2NFNjSWd3TVFhd1VmaEJuTHpmSXpvNkVYeUFCamtKbw?oc=5", "source_name": "SMH.com.au", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep (IMMP) director details Ordinary Shares and performance rights", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQMklPa2Q2QlU2N3BvcWNrWWs2Q1pUUFNRc2lEVUZCSmxhbmZzSHBRWkpQSG1wQUhBRVhBa0tpN0ljOFpCOFhMQVBFQjFuek83eWNKdk9oOTlVLXQtWjlxbHlMRDdOMGtTOXNXQVZUek9WaVBnWGNYNTdhQXdZdU5KYnhWaGtRaWVXYlBCUDNZeUZwVWVJWlhGanhicVdRWUdKM3dseEJ4bFhOV2hxTl9xbXpjZVhfNnNOS2NTSi1xaw?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep (IMM) Stock Doubles on FDA Orphan Drug Win for Rare Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMiT0FVX3lxTE9UeWxsMzBpeFZ5SmlnMUdDTGhhMExBVmJRR015Nk1ZM1ktZXN6a1M1eXJzVnZTaE85WFdzT1RDT2YzdG1tcmVhWDlCYUkwUE0?oc=5", "source_name": "MEXC", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep (ASX:IMM) wins FDA orphan status as efti Phase 2 hits 51.5% endpoint", "summary": "", "url": "https://news.google.com/rss/articles/CBMiT0FVX3lxTE9fUGVZNzRvSUZhYlBjclRsRjN6M2xYX2tjeHBTWlJPODgtYVRwZkxaVC16ZDBHNThNMS1nNEpQVzJZWTg4T1RiTHRsVXQ5aEU?oc=5", "source_name": "Stocks Down Under", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ASX Runners of the Week: Immutep, Blue Star Helium & Patagonia", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxNR3NweTFCQl80UnpRaDBoa3NLbzVSN0g0Y1hIbFcyWVA0bkFFcXd5dW05R1l2ZHJsaXVtOVI0MDh6ZFZyLV9hVm9wOW00WWtIdTcweFFzQmNjMUhNa25IX1FzSnB5bktKUFBTcndVMDdyRWZEUVYtaDduRThQbzRFbE1RQ1gzOUREMmVOU2MzR3M3WWw1R1FpUnNldFJCOElnRVhRY0Jqd0x5NHlNX1NUa1dudjFwNWlXTG1GeUV5c0hVVEU?oc=5", "source_name": "SMH.com.au", "published_at": "2026-03-20T07:00:00+00:00", "published_display": "20 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep stock plummets 90% on efti phase III failure in NSCLC", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQLXZfQWNxbm4tQWN4MEdLWE5kMS1nM0JEZm85dGtvZ2NFSlZvUXM0U1ZpRmtGcWdZSXVQMWhwY2pZUmczUTdvVVU3aExuZ3lSNnBxeGdOZFJ3SG45bk5DUTFvV0ttY0ViSEN2bTVYdHVNNjlzSDgtMHpuTzRmRlZDSkpRNVZuMHZqQ2ZKRWlhU25vRW5kRmhDZWV5ZkM1V2FScW5Z?oc=5", "source_name": "BioWorld News", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep's phase 3 failure for immunotherapy surprises analysts, sinks stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNT1M0U2piUzQ2VVFDTjFRWV8yeGZUZDZ6QjM2b2dobXpGUEE3YUZWVU82N3VUeFdpc09LWk1heTY3WXVCb2Y4T2FsUlE0NGU3bTZOQkh3MGxYNXd6YU0xUWVwZUpfSUx6RGlYMGRmbkJOc01tMjhvRmxsRnJweFhPamlUa1pGNUktWlJvZmtjQTM3b25POWJRV1pYdXV6ZE9fTUhDdEZoWXJOS0U?oc=5", "source_name": "Fierce Biotech", "published_at": "2026-03-13T07:00:00+00:00", "published_display": "13 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inside Biotech: Phase III setback sends Immutep shares into freefall", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxOUUxIX3NKdzhDVlZzQlo5eFRPdTMxcTRRTDJOSHRfcmhXNFhRWmN0YmRCekRKY0JZQ1ZhMXJiMjNmMlNMWkJVY0lyYjJXamk1RmxLa1FydktIWGxtZ190VzluOFNUa2psNmlxa3NuV05XdDBSamlpNW9MNmJ3X0RWbVRSUkg4WnF3WFc3aFlfM0UzcWh1RlA1U1NfTk5FN2x3bGlEQXF2ZjVxOFV2UDZybWVJS1ZHTjdzTndHZ0twOXVfQmtEaW00VzdTLW5PaWZ6UEZWZjNTaHY?oc=5", "source_name": "Proactive financial news", "published_at": "2026-03-13T07:00:00+00:00", "published_display": "13 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep crashes 90% as Phase III lung cancer trial discontinued", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNTHN0ejJjNllDTTVEc3hrODlFYVpJZTZnRGY1OUpZenY3Y3htNV9Ba0dfQzZkTDVPLUZza3FkSlJ2M3NsZnJidS1aOEV5X09vaFM0YVJhcTJ2c0dLX0dJa2ZFRVBlT2dROUJLSTJOT2t2RWhFdTJ3S2N6b1cwUWxxVjlCLXFSM1ZXS1Q4TlBhdTNWR0c4U0UxNF9OWWZrXzA?oc=5", "source_name": "Market Index", "published_at": "2026-03-13T07:00:00+00:00", "published_display": "13 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep stock plunges 80% after lung cancer trial halted", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPaFdudFFUbFJveXZEaVlGcXY5T1JNdjlNbFJnUzBaN2FfeElsRlJ5QnljbWFEMHFvNzlLZUtKY0d4c2ZLd1hjQnlWMzR3TmREQkhqMWpQQWdrSTdzSlAwdGxPWUVoMWJ6Vnd2NnlubVNJa2c1T1hmUkF6aXNLcHljbXpsSjFPT1lVWEcxaktoM0t5YzNrUFFGTUJkc2dEOTEyQUd5M21lTEFZTmhRN3l2NU1IU1Y0OHgy?oc=5", "source_name": "Investing.com", "published_at": "2026-03-13T07:00:00+00:00", "published_display": "13 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep (ASX:IMM) Stock Crashes 88.60% After Phase III Trial Failure: What Investors Need to Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxQanZEUTJGTXZLLU5uT1BDeUJWZ3Z6LVhOQjR2c0hZUkpNT1hvRTZ1b2YxODNnVE05TjJ0SG4wbDgyTTYyZ2RCNG9sZTlUSDN0UXpCSTJsN1FlYTh0MGxFdXFEZmFWTkMxRDVtMHo4X2NfaGpMTEpBLWUxdDlnZy1aaS16bTh3d1ZXV043clh2UXl4VzQ5RTY0N1VFLWw3cWU0LWFjWV8yV1FwWHgxTFFsSFRMcUJsZVRSSjVJamw2N3hOM0FLVU8xVi1McnM?oc=5", "source_name": "Kalkine", "published_at": "2026-03-13T07:00:00+00:00", "published_display": "13 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why the Immutep share price is halted today", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxOc1dlaHR1eWVSYk80QVJjMUYwV3lMU2dDdE16cGlZMW9tTlJNd25LYlRVT3JSa3F3V3cyUzVmdEhVT3d5cVBHZXpkeUQyNENTaTVyQm1DY0FLZ3ZidFdFcDN5blp4WEUyOC1YLVZTYmx2ZXRXMV9RU01MMlozamk3OHREVW42dw?oc=5", "source_name": "The Motley Fool Australia", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep H1 2026 Loss Worsening Challenges Bullish Revenue Growth Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep Limited (ASX:IMM) is largely controlled by institutional shareholders who own 50% of the company", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxPM1hXR0daWXhFQVZ2QnI2d3hoRG1TTTItbF9lMDV1RDhOSzg0eVA4MGY3end4cEpQSkdhaEhSX2tmMkxTZmJvRGZkbTRNY1d0anA4RjFka2dEaU8tZkhQV2F6YXF2OEZ0Z05oRl9EUWlIOXZjcWpRR014QUJRTVYyZ1RkNA?oc=5", "source_name": "Market source", "published_at": "2026-02-09T08:00:00+00:00", "published_display": "09 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ASX Penny Stocks Spotlight: Immutep And Two More To Consider", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-13T08:00:00+00:00", "published_display": "13 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep (ASX:IMM): Valuation Check After Dr. Reddy\u2019s Licensing Deal and New Phase II Breast Cancer Data", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-10T08:00:00+00:00", "published_display": "10 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep shares rocket on AU$528M deal with Dr. Reddy\u2019s", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxPcDZ6REVuZjBqY0pIRzhXb0dqMzhBdlducGxaZUZwQlpBQlpKVS1KTENrNzQ3WHFxcWt4ckt1dTZnMldiN1RBZVFzTWlEaFI1QjBLeW5Kcy1ncW5vb0NhZWtfdi1KMGtrSEJhUEdNaXNiRm0wLWpDNUZ2Y3JhaGsxdE9VeWRHbXRMWjNOLXQtd0Rjdzlsc1I0?oc=5", "source_name": "BioWorld News", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ASX Penny Stock Highlights: Immutep And 2 Other Noteworthy Picks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxPdnYyVmhxcHRxeTkzM0drbmVKVjJNTkhpdUp3Q3lfRzc2MTlWeHRsYnN0TG9oNmNzaUVqQU5KREpVS1l5ekpCRzZjWkNZTzZOd1pTNTVqUHpiTGFCX1Z1RkZBN1F0dW5zUVZLVjhoRy1Pc3FiN2xxNUwtLXkwOC1DcHJfbjVobGM?oc=5", "source_name": "Market source", "published_at": "2025-11-16T08:00:00+00:00", "published_display": "16 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Not Very Worried About Immutep's (ASX:IMM) Cash Burn Rate", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxOVE1vY1d0QVJYVjBXdmJZdUxTeHF5bkpxYjhnUzY0N2U1VmpWNlRQeXp5SWtELV9YelRTXzlLVGNma3lWSlV1cDI4QTZ0cjNGbnM3OEcwaXBQb0xfMEpfdlNPWTc3NU1ja1E3ajJzZHd3c2lYTW1oSnA0ME1PNEx4S2tB?oc=5", "source_name": "Market source", "published_at": "2025-09-28T07:00:00+00:00", "published_display": "28 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Immutep Shares Rocket Nearly 15% as Immunotherapy Momentum Returns to the ASX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOTmhpZnpnWXRQZWRwbXNHc1JDQV94ZWYwYXhGZ1JfUVN4VDdjMzN0Uk1iaHBjRTgyeUtVd2d3RW1xVGtaY3YzMGp3ODBpcjNZTkQtcW1WbkpQR1FGS196bm1xbS1nb0xpRXZpTlY1NFJiN2dRRlB0MDU4WjVYei1GSjVSRlNEeFk1eDF3UEwwNGtKMmNQcjNzclJCakZLT2ZvenVzMi1Jb1hWV2V5WnR0dzlvTk5NN3Z3?oc=5", "source_name": "Kalkine", "published_at": "2026-07-13T08:19:00+00:00", "published_display": "13 Jul 2026 08:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Immutep (ASX: IMM) Jump 13.73%?", "summary": "", "url": "https://news.google.com/rss/articles/CBMifEFVX3lxTE5XYXlvSlc1MTlaTUt5ZGZuckRQS3RJRzU2Z2Mza3BObkxERjhyN3VFdGFjNDA4V0M2YWhTNzh3d3QtbkdpOXdtdDFtTW5mU0pTZ3J0eWNTVGE5ZDhQQzhtdUY5bUFReUlLZ0ZBU2tJREVuQUx4V01OQ01FM24?oc=5", "source_name": "Kalkine", "published_at": "2026-07-13T06:32:00+00:00", "published_display": "13 Jul 2026 06:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep (ASX:IMM) Shares Surge Nearly 14% as Healthcare Momentum Grabs the ASX Spotlight", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNNmNPd3ZRWmtZRTVBdFNfWWhzVU5pcjdCbkh3U3g2MG5kcnFfNnBiUmtnTWJxbUhWblVHQ1Z1WXdEVlNBQW5ybFduRnpCcElSUVJQbGhCYUxEODMyaDhWRXRSVnNmYy02WkJ5VGVSc2RZNmNTeHIwQmo1RzdiT3BKRkZiX21LY0hoeUt6X2cxTjhQenVKRG5TWTE4bHp1dndtQllxVjlQVXVDSHQ2ZVBUd3dldGR4RU5TWmZxaXlhNVY?oc=5", "source_name": "Kalkine", "published_at": "2026-07-13T04:30:00+00:00", "published_display": "13 Jul 2026 04:30", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep (ASX:IMM) posts 30.9-month survival as TACTI-004 forensics finally get interesting", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxQUFYtZ0FxX2NCaklsY2FSRC1hOFJUSWtaLThGTUphUnRaRUFYQ1JuR0lrTWptWDRia2RmUWhHUkZoQXlwb1F4TURHckY5LWlmQzM2ckNkbHpCQkVIRi02Z3BwU0o0QUtaRkxja3Q0TTMyS0o0N05lN2N0NFdzSllaOGVCZDQ4WVBx?oc=5", "source_name": "Stocks Down Under", "published_at": "2026-07-13T00:41:14+00:00", "published_display": "13 Jul 2026 00:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep (ASX:IMM): Biotech Momentum Returns as This ASX Healthcare Stock Climbs", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxObzk5V3JVM1F3cUNDR3ZwSHpPMDFfQ0lITmlOdkVCUy13cWIzMWhZSUVfTHZfNU9UT2tpV2ZfaXJUNGtsckxWRnVDZWd5eVR0NVBBLV9fb09KY2xWQUcyTzI1SnRrSDBBZC02QlNVdlU4ZXMyamtNSllJNzhoZWVDTXRpUU1hQUlmTkR6cEJuWGFLd0ZLcXVEWkR6MVB3YXl6QVpVTnY1blNYOVBjRmR6RmotZWg?oc=5", "source_name": "Kalkine", "published_at": "2026-07-01T07:37:00+00:00", "published_display": "01 Jul 2026 07:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep (ASX:IMM): Why These ASX Penny Stocks Are Drawing Attention", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNTkRyM1pERUd5VVBnSlgwMGtBcG1iZnUxblVyMEtQZmJydFNjaXFwZVQxdmMtZGk3SFpyZGdKWnlsMEVmS2VTZkFyUVZUczBGMUNsWDJGUTFIVVRaUGtRck5vbkVpTFNoTnE3cEIwajQ2WWRaWmNvSGlCUHRqUi1UTVpFSnJVanlBVmt3VjR1QndfNWpTQ1JZWGtmVmFUTURuMVBIdjBQSmpKWV9hRENiOE15b0I?oc=5", "source_name": "Kalkine Media", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ASX Penny Stocks: Immutep And Two More Companies To Watch", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOQVVZcjBYempwbzdyMU1tUnM0SjlHRC1Qc1A0NGliUGtaUlhBT3FiT2RKSFNPY0d4bVBBMzhtVjJKMFZXREFWbzZYYXpkVG4xUU1TbzNmd1psVG1SZ2puZHA4cGlJcVA5Vy1lYzJPMndMeG9qOEpLYjhEOXZJTWZWRG8ySks3UjdoNjI1LUpKT1hjN0VaSTFQV3VCSlNBNGJqWUJvNGphM1FLYzkwV1BvQkVIZWxqbThFZzFleXNmSWZzT3pzSU9xTTNB0gHPAUFVX3lxTE0ya3VhRW5INlBYYVNVekxmZkZCOTV2TXVhNnlNOHNlX1RvUXJsbExsU0RBTk1VUHJiSFB5Z001NEw2ZWs4dDdFMFJvbjJmSGtJenBScm9pRGdWMFhXc2dNNGlNZVc2ZjJZcVpGOFozcHNrYVQwSGdDRWVSTjdaX1BNS0Z2c29WVHQyY1BXLXFLTlUtd1ktMVo4Wk5RaEhIZllHVHRtN2tyM1RrUG5rUnhNdHZwcnU0ajJ2Mmp0dUtua0ZjRXJVSW5ZQnR1bnp0QQ?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Watching Immutep's (ASX:IMM) Cash Burn Situation", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxNUVV6TlpHREhid213QkJfSFJ6U2F0T2FtOEFXVnVxU3FGVTNsU0ZkWk9QVHRlVkdJck9MNm5jLW5GSXdXS29wN2FfVW5MSXRVTnhsXzB0S2xGYW9Id0g3SXhuNWU0RGJiWS1uUWJkLU0yNngtaXhJUnpUcUl1U18wV3NZZS1xV0NvOEl2VnUzeVM0Z1FiWFlEanhqajg5UVd6NjhZZ0NpQ3lCZTZmMlF4ZEdybWlFN2ZuREsxcDA1d2hxMk5vN3BmVVNFd19QU21UUHVsT25iTHJrZkHSAeABQVVfeXFMTXBHYmliTUZ2N0FNVzVjY3hDYVp5dUJvbXdQUVhrdmhUR0RkV0FrdFM3dmt6emZtZzBjWmZHeGxzN3NMNmsyRW1PNUV6Sm5obDJ3YW9GMVNzUTdSdWVGOEEwS0pTbjBvM2RqbjUzWnF2ODlvOUh1S1QyeWFKZ1lGTHNCVjJVSFl5M1plVnphNTh5OHc2dFM2aU5LSThCTm9BQzVmQnZZWFFIdTUtYlVONlQwVVg0T3U3MEEzVjZobFdMd2Y2ZkhXWHo3RkFsS1o4VHA0akV3TU5laHlfUmtjRnE?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan Chase Ceases to Be Substantial Holder in Immutep", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOU1FSWUZwYkZkd25wTEJDSlNnejlOb2xMYjBjNnJuUzI4bmUyaERWUjBBeGVobFVaN1k4dEo4OEFKa3FZTWFpZnpFWHNPMXBNZjd4dFJKc0hmZUpEZUg3Rm8tc1ZVM2VUTmRMWGljTGt0bHlJQ1MwU1liU3g2UHZDdzl4R1d4ZHZ1VUtuOE1NaXF1Z0hkb2pyalhra1NEM0FzTGpFY1VXSW9nb09INmc?oc=5", "source_name": "TipRanks", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Immutep (ASX:IMM) In A Good Position To Deliver On Growth Plans?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPdmlqVTd0Qm5NT1gwRXJPUlYtWm9YNmdVaHBGTUJtaExCQ1puSHNWRnFXaVplakxjbTNzZ2tQRWJQa3BHem9GMGlBbjFkNUR5V3ZwOEdxcWE5VU1TLUphN1dwV2kta0pLbzdOdko2QXYyVm1RWmxtcV9kY3RVRDg3UGlOR1M2d0c2U1FZdTRnNG5IRE9ZNEhyTVpB?oc=5", "source_name": "Market source", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ASX Runners of the Week: Bison, Genetic Signatures, Narryer & Immutep", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNSlFJcS1HbWdycUhMaE9ZWFVxcmxlRGN4a2ctRVBYT3RJdFFoejBrZzZNUU51N2d2TmlmcDJUVXFmZTBTQ1lEZEFMR3F0bXlXYmtiRG1HWUtfbi1MMERJLU9zaXF2WFFLSU1RbjAyU0VJcGR0Z0pOQ20yMEdOYWdLZjMta21YaS1RakMtczNGcUJnY1NjSVRkQ1RZMWZPdXdDc1RZTmtNUlU3dzM2NFNjSWd3TVFhd1VmaEJuTHpmSXpvNkVYeUFCamtKbw?oc=5", "source_name": "SMH.com.au", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep (IMMP) director details Ordinary Shares and performance rights", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQMklPa2Q2QlU2N3BvcWNrWWs2Q1pUUFNRc2lEVUZCSmxhbmZzSHBRWkpQSG1wQUhBRVhBa0tpN0ljOFpCOFhMQVBFQjFuek83eWNKdk9oOTlVLXQtWjlxbHlMRDdOMGtTOXNXQVZUek9WaVBnWGNYNTdhQXdZdU5KYnhWaGtRaWVXYlBCUDNZeUZwVWVJWlhGanhicVdRWUdKM3dseEJ4bFhOV2hxTl9xbXpjZVhfNnNOS2NTSi1xaw?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep (IMM) Stock Doubles on FDA Orphan Drug Win for Rare Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMiT0FVX3lxTE9UeWxsMzBpeFZ5SmlnMUdDTGhhMExBVmJRR015Nk1ZM1ktZXN6a1M1eXJzVnZTaE85WFdzT1RDT2YzdG1tcmVhWDlCYUkwUE0?oc=5", "source_name": "MEXC", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep (ASX:IMM) wins FDA orphan status as efti Phase 2 hits 51.5% endpoint", "summary": "", "url": "https://news.google.com/rss/articles/CBMiT0FVX3lxTE9fUGVZNzRvSUZhYlBjclRsRjN6M2xYX2tjeHBTWlJPODgtYVRwZkxaVC16ZDBHNThNMS1nNEpQVzJZWTg4T1RiTHRsVXQ5aEU?oc=5", "source_name": "Stocks Down Under", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ASX Runners of the Week: Immutep, Blue Star Helium & Patagonia", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxNR3NweTFCQl80UnpRaDBoa3NLbzVSN0g0Y1hIbFcyWVA0bkFFcXd5dW05R1l2ZHJsaXVtOVI0MDh6ZFZyLV9hVm9wOW00WWtIdTcweFFzQmNjMUhNa25IX1FzSnB5bktKUFBTcndVMDdyRWZEUVYtaDduRThQbzRFbE1RQ1gzOUREMmVOU2MzR3M3WWw1R1FpUnNldFJCOElnRVhRY0Jqd0x5NHlNX1NUa1dudjFwNWlXTG1GeUV5c0hVVEU?oc=5", "source_name": "SMH.com.au", "published_at": "2026-03-20T07:00:00+00:00", "published_display": "20 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep stock plummets 90% on efti phase III failure in NSCLC", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQLXZfQWNxbm4tQWN4MEdLWE5kMS1nM0JEZm85dGtvZ2NFSlZvUXM0U1ZpRmtGcWdZSXVQMWhwY2pZUmczUTdvVVU3aExuZ3lSNnBxeGdOZFJ3SG45bk5DUTFvV0ttY0ViSEN2bTVYdHVNNjlzSDgtMHpuTzRmRlZDSkpRNVZuMHZqQ2ZKRWlhU25vRW5kRmhDZWV5ZkM1V2FScW5Z?oc=5", "source_name": "BioWorld News", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep's phase 3 failure for immunotherapy surprises analysts, sinks stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNT1M0U2piUzQ2VVFDTjFRWV8yeGZUZDZ6QjM2b2dobXpGUEE3YUZWVU82N3VUeFdpc09LWk1heTY3WXVCb2Y4T2FsUlE0NGU3bTZOQkh3MGxYNXd6YU0xUWVwZUpfSUx6RGlYMGRmbkJOc01tMjhvRmxsRnJweFhPamlUa1pGNUktWlJvZmtjQTM3b25POWJRV1pYdXV6ZE9fTUhDdEZoWXJOS0U?oc=5", "source_name": "Fierce Biotech", "published_at": "2026-03-13T07:00:00+00:00", "published_display": "13 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inside Biotech: Phase III setback sends Immutep shares into freefall", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxOUUxIX3NKdzhDVlZzQlo5eFRPdTMxcTRRTDJOSHRfcmhXNFhRWmN0YmRCekRKY0JZQ1ZhMXJiMjNmMlNMWkJVY0lyYjJXamk1RmxLa1FydktIWGxtZ190VzluOFNUa2psNmlxa3NuV05XdDBSamlpNW9MNmJ3X0RWbVRSUkg4WnF3WFc3aFlfM0UzcWh1RlA1U1NfTk5FN2x3bGlEQXF2ZjVxOFV2UDZybWVJS1ZHTjdzTndHZ0twOXVfQmtEaW00VzdTLW5PaWZ6UEZWZjNTaHY?oc=5", "source_name": "Proactive financial news", "published_at": "2026-03-13T07:00:00+00:00", "published_display": "13 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep crashes 90% as Phase III lung cancer trial discontinued", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNTHN0ejJjNllDTTVEc3hrODlFYVpJZTZnRGY1OUpZenY3Y3htNV9Ba0dfQzZkTDVPLUZza3FkSlJ2M3NsZnJidS1aOEV5X09vaFM0YVJhcTJ2c0dLX0dJa2ZFRVBlT2dROUJLSTJOT2t2RWhFdTJ3S2N6b1cwUWxxVjlCLXFSM1ZXS1Q4TlBhdTNWR0c4U0UxNF9OWWZrXzA?oc=5", "source_name": "Market Index", "published_at": "2026-03-13T07:00:00+00:00", "published_display": "13 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep stock plunges 80% after lung cancer trial halted", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPaFdudFFUbFJveXZEaVlGcXY5T1JNdjlNbFJnUzBaN2FfeElsRlJ5QnljbWFEMHFvNzlLZUtKY0d4c2ZLd1hjQnlWMzR3TmREQkhqMWpQQWdrSTdzSlAwdGxPWUVoMWJ6Vnd2NnlubVNJa2c1T1hmUkF6aXNLcHljbXpsSjFPT1lVWEcxaktoM0t5YzNrUFFGTUJkc2dEOTEyQUd5M21lTEFZTmhRN3l2NU1IU1Y0OHgy?oc=5", "source_name": "Investing.com", "published_at": "2026-03-13T07:00:00+00:00", "published_display": "13 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep (ASX:IMM) Stock Crashes 88.60% After Phase III Trial Failure: What Investors Need to Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxQanZEUTJGTXZLLU5uT1BDeUJWZ3Z6LVhOQjR2c0hZUkpNT1hvRTZ1b2YxODNnVE05TjJ0SG4wbDgyTTYyZ2RCNG9sZTlUSDN0UXpCSTJsN1FlYTh0MGxFdXFEZmFWTkMxRDVtMHo4X2NfaGpMTEpBLWUxdDlnZy1aaS16bTh3d1ZXV043clh2UXl4VzQ5RTY0N1VFLWw3cWU0LWFjWV8yV1FwWHgxTFFsSFRMcUJsZVRSSjVJamw2N3hOM0FLVU8xVi1McnM?oc=5", "source_name": "Kalkine", "published_at": "2026-03-13T07:00:00+00:00", "published_display": "13 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why the Immutep share price is halted today", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxOc1dlaHR1eWVSYk80QVJjMUYwV3lMU2dDdE16cGlZMW9tTlJNd25LYlRVT3JSa3F3V3cyUzVmdEhVT3d5cVBHZXpkeUQyNENTaTVyQm1DY0FLZ3ZidFdFcDN5blp4WEUyOC1YLVZTYmx2ZXRXMV9RU01MMlozamk3OHREVW42dw?oc=5", "source_name": "The Motley Fool Australia", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep H1 2026 Loss Worsening Challenges Bullish Revenue Growth Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep Limited (ASX:IMM) is largely controlled by institutional shareholders who own 50% of the company", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxPM1hXR0daWXhFQVZ2QnI2d3hoRG1TTTItbF9lMDV1RDhOSzg0eVA4MGY3end4cEpQSkdhaEhSX2tmMkxTZmJvRGZkbTRNY1d0anA4RjFka2dEaU8tZkhQV2F6YXF2OEZ0Z05oRl9EUWlIOXZjcWpRR014QUJRTVYyZ1RkNA?oc=5", "source_name": "Market source", "published_at": "2026-02-09T08:00:00+00:00", "published_display": "09 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ASX Penny Stocks Spotlight: Immutep And Two More To Consider", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-13T08:00:00+00:00", "published_display": "13 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep (ASX:IMM): Valuation Check After Dr. Reddy\u2019s Licensing Deal and New Phase II Breast Cancer Data", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-10T08:00:00+00:00", "published_display": "10 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep shares rocket on AU$528M deal with Dr. Reddy\u2019s", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxPcDZ6REVuZjBqY0pIRzhXb0dqMzhBdlducGxaZUZwQlpBQlpKVS1KTENrNzQ3WHFxcWt4ckt1dTZnMldiN1RBZVFzTWlEaFI1QjBLeW5Kcy1ncW5vb0NhZWtfdi1KMGtrSEJhUEdNaXNiRm0wLWpDNUZ2Y3JhaGsxdE9VeWRHbXRMWjNOLXQtd0Rjdzlsc1I0?oc=5", "source_name": "BioWorld News", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ASX Penny Stock Highlights: Immutep And 2 Other Noteworthy Picks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxPdnYyVmhxcHRxeTkzM0drbmVKVjJNTkhpdUp3Q3lfRzc2MTlWeHRsYnN0TG9oNmNzaUVqQU5KREpVS1l5ekpCRzZjWkNZTzZOd1pTNTVqUHpiTGFCX1Z1RkZBN1F0dW5zUVZLVjhoRy1Pc3FiN2xxNUwtLXkwOC1DcHJfbjVobGM?oc=5", "source_name": "Market source", "published_at": "2025-11-16T08:00:00+00:00", "published_display": "16 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Not Very Worried About Immutep's (ASX:IMM) Cash Burn Rate", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxOVE1vY1d0QVJYVjBXdmJZdUxTeHF5bkpxYjhnUzY0N2U1VmpWNlRQeXp5SWtELV9YelRTXzlLVGNma3lWSlV1cDI4QTZ0cjNGbnM3OEcwaXBQb0xfMEpfdlNPWTc3NU1ja1E3ajJzZHd3c2lYTW1oSnA0ME1PNEx4S2tB?oc=5", "source_name": "Market source", "published_at": "2025-09-28T07:00:00+00:00", "published_display": "28 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 84, "total_relevant": 29, "sentiment_summary": {"positive": 3, "negative": 0, "neutral": 26, "score": 52, "total": 29, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 89, "events": [{"event": "general", "label": "Market update", "weight": 13.2, "count": 24}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "earnings", "label": "Earnings", "weight": 0.55, "count": 1}], "positive_events": 3, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 0.05, "latest_week": "2026-07-10", "one_week_move": -7.3, "four_week_move": 8.5, "twelve_week_move": -26.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.232028, "market_dynamics_buy_signal": false, "relative_strength": -77.529189, "fair_value_gap": -82.6, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 44.8349, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-7.3% over one week, +8.5% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 64, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Kalkine", "count": 5}, {"label": "simplywall.st", "count": 5}, {"label": "Market source", "count": 4}, {"label": "Stocks Down Under", "count": 2}, {"label": "SMH.com.au", "count": 2}, {"label": "BioWorld News", "count": 2}, {"label": "Kalkine Media", "count": 1}, {"label": "TipRanks", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 29}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 24}, {"label": "Balance sheet", "count": 2}, {"label": "Deals and strategy", "count": 2}, {"label": "Earnings", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "89/100 classification confidence."}, {"label": "Company focus", "value": "29", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-7.3% over one week, +8.5% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Immutep Shares Rocket Nearly 15% as Immunotherapy Momentum Returns to the ASX"}], "updated_at": "2026-07-18T03:28:32.188811+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}